Treatment of Antiphospholipid Syndrome After a First Unprovoked Venous Thrombosis

In patients with definite antiphospholipid syndrome (APS), a first unprovoked venous thrombotic event marks a high-risk inflection point. Because no reversible provoking factor can be addressed, the therapeutic approach differs from provoked thrombosis and carries specific long-term implications.

Clinical Scenario

Definite antiphospholipid syndrome with a first unprovoked venous thrombosis — confirmed APS criteria met, no identifiable transient provoking factor for the thrombotic event.

Treatment Approach

The standard approach begins with an initial parenteral anticoagulant, followed by a transition to long-term oral anticoagulant therapy directed at a defined therapeutic target. In patients who cannot maintain that target or have specific contraindications, an alternative anticoagulant class may be considered. Complete regimen, selection criteria, and sequencing available in the structured protocol →

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/annrheumdis-2019-215213

In patients with definite APS and first venous thrombosis: A. Treatment with VKA with a target INR 2–3 is recommended.
In patients with unprovoked first venous thrombosis, anticoagulation should be continued long term.
In patients with APS and first venous thrombosis, after an initial therapy with unfractionated heparin (UFH) or LMWH and bridging therapy of heparin plus VKA, treatment with VKA with a target INR of 2–3 is recommended.
DOACs could be considered in patients not able to achieve a target INR despite good adherence to VKA or those with contraindications to VKA (eg, allergy or intolerance to VKA).

View source ↗